RxDoctor Payments Data

Monali Patel, MD

Neurology · San Diego, CANPI 1326290339

Payments from drug & device makers

$187,797in general payments, 2019–2025

Across 1,372 payments — averaging $136.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$45K
  • Teva Pharmaceuticals USA, Inc.$39K
  • Supernus Pharmaceuticals, Inc.$29K
  • Neurelis, Inc.$20K
  • Biohaven Pharmaceutical Holding Company Ltd.$17K
  • Biohaven Pharmaceuticals, Inc.$15K
  • plus $23K from 54 others

What the payments were for

  • Consulting fees$5,0603%
  • Speaking & faculty fees$147,40778%
  • Travel & lodging$9,3765%
  • Food & beverage$25,71514%
  • Education$2390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)170$44,917
Teva Pharmaceuticals USA, Inc.106$39,285
Supernus Pharmaceuticals, Inc.70$28,600
Neurelis, Inc.82$19,806
Biohaven Pharmaceutical Holding Company Ltd.40$16,694
Biohaven Pharmaceuticals, Inc.31$14,638
Portola Pharmaceuticals, LLC11$5,782
UCB, Inc.85$1,853
Lundbeck LLC44$1,254
Amgen(2 entities)59$1,211
Novartis92$1,126
AstraZeneca(2 entities)16$1,121
Livanova USA, Inc.14$1,033
Biogen44$950
Eisai Inc.42$808
Adamas Pharmaceuticals, Inc.40$542
Sanofi18$468
GE HealthCare16$455
Lilly USA, LLC34$454
Pfizer21$415
Scilex Pharmaceuticals Inc.24$414
Johnson & Johnson(2 entities)16$354
SK Life Science, Inc.15$353
CSL Behring19$290
Sunovion Pharmaceuticals Inc.21$283
Upsher-smith Laboratories LLC13$280
Boston Scientific8$270
Neurocrine Biosciences, Inc.9$255
TG Therapeutics, Inc.12$253
Zyla Life Sciences, Inc.52$239
Octapharma USA, Inc.6$224
Bristol Myers Squibb11$200
Neurent Medical Limited2$193
Takeda Pharmaceuticals U.S.A., Inc.7$148
Si-bone, Inc.1$138
Genentech USA, Inc.7$136
Avanir Pharmaceuticals, Inc.8$124
Tanabe Pharma America, Inc.6$124
Alcon1$124
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)1$120
Acadia Pharmaceuticals Inc7$113
Vanda Pharmaceuticals Inc.5$111
Mallinckrodt Hospital Products Inc.4$92
Amneal Pharmaceuticals LLC6$91
Arbor Pharmaceuticals, Inc.6$91
Jazz Pharmaceuticals Inc.3$89
GRT US Holding, Inc.3$88
Alnylam Pharmaceuticals Inc.4$82
Tersera Therapeutics LLC6$78
Grifols USA, LLC4$77
Banner Life Sciences, LLC4$72
Insightec,inc3$71
Almatica Pharma LLC4$70
Abbott3$58
Bausch Health US, LLC3$51
Nevro Corp.3$49
Greenwich Biosciences, Inc.2$49
MDD US Operations, LLC2$47
Currax Pharmaceuticals LLC3$46
Medtronic(2 entities)2$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$187,797 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$390,132
Medicare patients
1,040
Services billed
3,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FycompaPerampanel12$15,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$808$15,81212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →